We are conducting an international clinical trial of the first specific treatment for Polycystic Ovary Syndrome (PCOS). The study is currently underway at the following locations:
- Norway: Norwegian University of Science and Technology in Trondheim.
- Denmark: Odense Universitets Hospital.
- Italy: Università Di Bologna.
- Turkey: Istambul University.
- Austria: Medizinische Universität Graz.
- Spain: Hospital Sant Joan de Déu in Barcelona and Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta.
Criteria for joining the clinical trial
Girls and women with Polycystic Ovary Syndrome (PCOS) who are:
- Between 12 and 23.9 years old
- Experiencing irregular menstruation
- Experiencing excess hair growth
More information and participation
For more information on the study and how to participate, please see the information and participation links below:
- Information in Norwegian and participation in Trondheim.
- Information in Danish and participation in Odense, Denmark.
- Information in Italian and participation in Bologna, Italy.
- Information in Turkish and participation in Istanbul, Turkey.
- Information in German and participation in Graz, Austria.
- Information in Spanish and participation in Barcelona or Girona, Spain.
About Polycystic Ovary Syndrome (PCOS)
PCOS affects between 5 and 10% of women of reproductive age and can cause increased body hair and acne, irregular menstrual periods, and fertility problems. It is the most common endocrine disorder in women of reproductive age but is still one of the most unknown pathologies among the general population. It can also lead to the development of other diseases such as type 2 diabetes, cancer before menopause, and anxiety or depression, which can greatly impact the quality of life for women affected by the condition.
Introducing SPIOMET4HEALTH to treat PCOS
For the first time, our clinical trial aims to treat the root cause of PCOS rather than just alleviating its symptoms. Currently, 98% of women with the condition are treated with oral contraceptives to control some of the symptoms.
The SPIOMET4HEALTH treatment consists of a daily tablet, which is a low-dose combination of three drugs that have been on the market for two or more decades (spironolactone, pioglitazone and metformin), which, together with a healthy lifestyle, could normalise hormones and ovulation, and thus reverse the alterations associated with PCOS. It is classified as phase II clinical trial.
The treatment will be carried out for one year, and the patient will be monitored for a further 6 months to check the changes that occur during and after the medication.
SPIOMET4HEALTH involves 17 organisations from 9 European countries. Hospitals, research centres, associations and high-profile companies working on PCOS all over Europe.
The project is coordinated by a research team from the Institut de Recerca Sant Joan de Déu (Barcelona, Spain), led by Dr Lourdes Ibáñez, winner of the Premi Nacional de Recerca de Catalunya in 2014 and recently awarded by two leading international institutions, such as the American Endocrine Society and the American Human Growth Foundation.